Robert Vescio

10.4k total citations
150 papers, 6.0k citations indexed

About

Robert Vescio is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert Vescio has authored 150 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hematology, 73 papers in Molecular Biology and 72 papers in Oncology. Recurrent topics in Robert Vescio's work include Multiple Myeloma Research and Treatments (105 papers), Protein Degradation and Inhibitors (41 papers) and Cancer Treatment and Pharmacology (23 papers). Robert Vescio is often cited by papers focused on Multiple Myeloma Research and Treatments (105 papers), Protein Degradation and Inhibitors (41 papers) and Cancer Treatment and Pharmacology (23 papers). Robert Vescio collaborates with scholars based in United States, Germany and Canada. Robert Vescio's co-authors include James R. Berenson, Alan Lichtenstein, Regina A. Swift, Yiping Tu, Gary J. Schiller, Hank H. Yang, Matthew B. Rettig, Robert H. Collins, Richard A. Koup and Jason M. Brenchley and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert Vescio

144 papers receiving 5.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Vescio 3.0k 3.0k 2.9k 878 591 150 6.0k
Torben Plesner 2.4k 0.8× 2.2k 0.7× 3.2k 1.1× 1.4k 1.5× 905 1.5× 169 5.6k
Martine Amiot 2.7k 0.9× 4.8k 1.6× 2.9k 1.0× 1.8k 2.1× 799 1.4× 131 7.9k
Ravi Vij 4.1k 1.3× 4.3k 1.4× 6.5k 2.2× 1.6k 1.8× 1.1k 1.8× 469 9.6k
Stefan Knop 2.1k 0.7× 1.9k 0.7× 1.9k 0.6× 641 0.7× 396 0.7× 152 4.4k
John P. Chute 1.5k 0.5× 2.0k 0.7× 1.9k 0.7× 1.0k 1.2× 865 1.5× 135 5.0k
David A. Rizzieri 2.5k 0.8× 3.0k 1.0× 4.3k 1.5× 1.6k 1.8× 1.6k 2.7× 309 8.1k
Ulrich Jäger 1.7k 0.5× 1.8k 0.6× 2.4k 0.8× 1.2k 1.3× 1.2k 2.0× 172 5.7k
Keith Stockerl‐Goldstein 1.8k 0.6× 1.7k 0.6× 3.3k 1.1× 1.4k 1.6× 671 1.1× 200 5.2k
Bertrand Arnulf 1.6k 0.5× 2.4k 0.8× 2.3k 0.8× 1.0k 1.2× 763 1.3× 167 4.8k
Matthias Theobald 2.2k 0.7× 1.7k 0.6× 2.4k 0.8× 2.4k 2.8× 534 0.9× 145 5.9k

Countries citing papers authored by Robert Vescio

Since Specialization
Citations

This map shows the geographic impact of Robert Vescio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Vescio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Vescio more than expected).

Fields of papers citing papers by Robert Vescio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Vescio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Vescio. The network helps show where Robert Vescio may publish in the future.

Co-authorship network of co-authors of Robert Vescio

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Vescio. A scholar is included among the top collaborators of Robert Vescio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Vescio. Robert Vescio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shoji, Jun, Ashley Vo, Edmund Huang, et al.. (2025). Daratumumab for Treatment of Recurrent FSGS and PGNMID in Kidney Transplant. American Journal of Transplantation. 25(8). S881–S881.
2.
Vo, Ashley, Edmund Huang, Xiaohai Zhang, et al.. (2025). Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up. American Journal of Transplantation. 25(8). S267–S267.
3.
Berenson, James R., Stephanie R. Rice, Ralph V. Boccia, et al.. (2023). A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone. Blood. 142(Supplement 1). 4753–4753. 1 indexed citations
4.
5.
Vescio, Robert, et al.. (2023). Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia. Blood. 142(Supplement 1). 7057–7057. 1 indexed citations
6.
Berenson, James R., Sean Bujarski, Tanya M. Spektor, et al.. (2022). A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematological Oncology. 40(5). 906–913. 8 indexed citations
7.
Spektor, Tanya M., Alberto Bessudo, Haresh Jhangiani, et al.. (2022). Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen. Experimental Hematology. 114. 54–60. 3 indexed citations
8.
Berenson, James R., Tanya M. Spektor, Regina A. Swift, et al.. (2020). A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 26(10). 2346–2353. 25 indexed citations
9.
Kittleson, M., Robert Cole, J. Patel, et al.. (2019). Mechanical circulatory support for cardiac amyloidosis. Clinical Transplantation. 33(10). e13663–e13663. 23 indexed citations
10.
Berenson, James R., Ori Yellin, Chien-Shing Chen, et al.. (2014). A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Supportive Care in Cancer. 23(6). 1503–1512. 27 indexed citations
11.
Terpos, Evangelos, Meletios Α. Dimopoulos, Orhan Sezer, et al.. (2010). The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 24(10). 1700–1712. 65 indexed citations
12.
Chen, Christine, Donna Reece, David S. Siegel, et al.. (2009). Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology. 146(2). 164–170. 62 indexed citations
13.
Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2009). Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology. 146(6). 619–626. 37 indexed citations
14.
Hussein, M. A., Frank D. Vrionis, Robert D. Allison, et al.. (2008). The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 22(8). 1479–1484. 46 indexed citations
15.
Chen, Tianling, James R. Berenson, Robert Vescio, et al.. (2002). Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases. The Journal of Clinical Pharmacology. 42(11). 1228–1236. 310 indexed citations
16.
Vescio, Robert, et al.. (2001). Malignant Multiple Myeloma (MM) Cells Express RANKL, A Moderator of Osteoclast Activation. Journal of Bone and Mineral Metabolism. 19. 94. 1 indexed citations
17.
Tasaka, Taizo, James R. Berenson, Robert Vescio, et al.. (1997). Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. British Journal of Haematology. 96(1). 98–102. 51 indexed citations
18.
Silverman, S, Robert Vescio, David Silver, et al.. (1996). Silicone Gel Implants and Monoclonal Gammopathies: Three Cases of Multiple Myeloma and the Prevalence of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Current topics in microbiology and immunology. 210. 367–374. 18 indexed citations
19.
Lichtenstein, Alan, Yiping Tu, Catherine Fady, Robert Vescio, & James R. Berenson. (1995). Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells. Cellular Immunology. 162(2). 248–255. 244 indexed citations
20.
Tu, Yiping, Fei Xu, A. Fleishman, et al.. (1990). BCL-X expression in multiple myeloma: possible indicator of chemoresistance.. Dialnet (Universidad de la Rioja). 58(2). 256–62. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Torben Plesner Breakdown of academic impact, for papers by Martine Amiot Breakdown of academic impact, for papers by Ravi Vij Breakdown of academic impact, for papers by Stefan Knop Breakdown of academic impact, for papers by John P. Chute Breakdown of academic impact, for papers by David A. Rizzieri Breakdown of academic impact, for papers by Ulrich Jäger Breakdown of academic impact, for papers by Keith Stockerl‐Goldstein Breakdown of academic impact, for papers by Bertrand Arnulf Breakdown of academic impact, for papers by Matthias Theobald
Rankless by CCL
2026